Unbiased Analysis of Today's Healthcare Issues

How do we measure the value of and pay for biomedical innovation?

Dana Goldman, Samuel Nussbaum, and Mark Linthicum have an interesting post on the Health Affairs blog about innovation, value measurement and pricing.  The article mentions the new Innovation and Value Initiative, where I serve as the Director of Research.  An excerpt is below. New pricing mechanisms are needed to effectively link prices to value; we […]

Read the rest of this entry »

Measuring Quality in Cancer Care

Identifying high-quality, cancer care is a laudable goal.  However, a recent article by Alvarnas (2016) says the way many are trying to measure quality of cancer care currently is inadequate.  Specifically: Quality and value are multidimensional, but the narrow focus of many quality measures undermines their effectiveness and meaningfulness. (Porter 2010) Quality and value measures are all […]

Read the rest of this entry »

Patient perspective on cancer care funding

Improvement in survival (a.k.a. efficiacy) clearly are important, but what other factors matter?  According to a systematic literature review by MacLeod, Harris and Mahal (2016), these factors include: patients favour funding for cancer medicines that improve health outcomes demonstrated by ‘clinical efficacy’ [Oh et al.], ‘prolonged survival’ [Goldman et al., Seabury et al. Lakdawalla et al.] and/or […]

Read the rest of this entry »

What is MACRA?

MACRA is the Medicare Access & CHIP Reauthorization Act, also know colloquially as the ‘permanent doc fix’.  Although MACRA is know for repealing the Sustainable Growth Rate (SGR) provisions that would have significantly cut physicians salaries (but was reversed every December), there are other provisions. Although physicians may take comfort in avoiding the year end doc […]

Read the rest of this entry »

NCCN Evidence Blocks

NCCN recently released a new approach to measure the value of cancer medicines. The approach–known as Evidence Blocks–evaluates medications on 5 dimensions: Efficacy of regimens, Safety of regimens, Quality and quantity of evidence for regimens, Consistency of evidence for regimens, and Affordability of regimens. Each criteria is ranked on a 1 to 5 block scale. […]

Read the rest of this entry »

ACC/AHA Statement on Measuring Treatment Value

The conventional premise governing performance measures and guideline recommendation…is that all healthcare professionals should act in the best interests of their patients without regard to costs. However, as the cost of medical care has increased, specialty societies are increasing considering the cost of care when selecting treatments. For instance, A recent survey reported that slightly […]

Read the rest of this entry »

Defining Healthcare ‘Value’

People today want high quality health care at lower cost (to be honest, people throughout history have always wanted better quality and lower cost).  However, defining the ‘value’ of medical services is not easy.  In fact, it is often difficult for companies to demonstrate to customers that they provide superior value.  Joe Paduda has a […]

Read the rest of this entry »